Advantage Alpha Capital Partners LP Sells 34,099 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Advantage Alpha Capital Partners LP lowered its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 42.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,151 shares of the biopharmaceutical company’s stock after selling 34,099 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Dynavax Technologies were worth $514,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares in the last quarter. US Bancorp DE raised its holdings in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in Dynavax Technologies during the 3rd quarter worth approximately $45,000. Nisa Investment Advisors LLC grew its holdings in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the last quarter. Finally, Algert Global LLC bought a new stake in Dynavax Technologies during the 2nd quarter worth approximately $140,000. Institutional investors own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DVAX. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.66 on Wednesday. The firm has a market cap of $1.66 billion, a PE ratio of 97.39 and a beta of 1.34. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The business’s 50 day moving average price is $11.56 and its two-hundred day moving average price is $11.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.